Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Obeldesivir in Children Under 5 Years With RSV Infection
jRCT2031240735Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Obeldesivir with Placebo (2 arms). Primary endpoints: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) Through Day 28, Percentage of Participants Experiencing Grade 3 or 4 Treatment-emergent Laboratory Abnormalities by Day 28 and 1 more. Started Apr 2025; status: completed.
02
Drugs
obeldesivir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031240735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240735.